ABOUT INDEXING BOARD ARCHIVES AUTHOR GUIDELINES SUBMIT PAPER AUTHOR'S PAGE NEWS, EVENTS CONTACT
REVISTA DE CHIMIE
Cite as: Rev. Chim.
https://doi.org/10.37358/Rev.Chim.1949

OSIM Nr. R102355
ISSN Online 2668-8212
ISSN Print: 1582-9049
ISSN-L: 1582-9049

REVISTA DE CHIMIE Latest Issue

LATEST ISSUE >>>

   Volume 76, 2025
   Volume 75, 2024
   Volume 74, 2023
   Volume 73, 2022
   Volume 72, 2021
   Volume 71, 2020
   Volume 70, 2019
   Volume 69, 2018
   Volume 68, 2017
   Volume 67, 2016
   Volume 66, 2015
   Volume 65, 2014
   Volume 64, 2013
   Volume 63, 2012
   Volume 62, 2011
   Volume 61, 2010
   Volume 60, 2009
   Volume 59, 2008
   Volume 58, 2007
 
<<<< back

Revista de Chimie (Rev. Chim.), Year 2016, Volume 67, Issue 10,





OANA VIOLA BADULESCU, MARIA MAGDALENA LEON, MADALINA MOCANU
Using Iron Chelators - deferasirox in the Treatment of Hypersiderosis

Abstract:

Hemosiderosis is a condition characterized by a pathological increase of iron levels in the body. One of the main etiologies of hemosiderosis is represented by massive transfusions of packed red blood cells, as it happens in major beta-thalassemia or in myelodysplastic syndromes, haematological disorders evolving with low values of haemoglobin which require transfusion frequently. Hypersideremia therapy consists of the administration of iron chelators. Deferasirox is a next generation iron chelator, which is administered to multiple transfused patients. It is used to prevent iron storage in deposits by increasing its excretion rate.The purpose of this paper is to highlight the role of the treatment with iron chelators, respectively Deferasirox in preventing the onset of hemosiderosis and its complications. We also intend to analyze aspects of the chemical and pharmacological profile of Deferasirox. We present the case of a 27 year-old man diagnosed with myelodysplastic syndrome of the refractory anemia type, in which increased transfusion treatment imposed by the severely low hemoglobin values, led to the risk of secondary hemosiderosis installation. We intend to emphasize the beneficial effect of iron chelators therapy, which prevents the installation of hypersideremia complications, reduces the transfusion requirements and improves patient’s quality of life. Keywords: iron, toxicity, deferasirox, hypersideremia

Issue: 2016, Volume 67, Issue 10
Pages:
download pdf   Download Pdf Article
Creative Commons License
This article is published under the Creative Commons Attribution 4.0 International License
 
<<<< back
 
PUBLISHING SECTION
Author Guidelines
 * Paper Drafting
 * Paper Template
 * Ethical Statement
 * Paper Submission
Ghidul Autorului (ro)
Submit Paper
Author's Page
Publishing Ethics
Peer Review Process
Open Access & Archiving Policy
 Search Authors
 LATEST NEWS
REvista de Chimie NUMAR OMAGIAL PETRU PONI.. detalii
REvista de Chimie Revista de Chimie - 70 de ani de aparitie neintrerupta.. detalii
dictionar English-Romanian Dictionary for Mechanical Engineering
(download pdf)
  News, Events
Crossref Member Badge
 DOI  logo
 Gold Open Access | Source=http://www.plos.org/  | Author=art designer at PLoS
Creative Commons License
 Conferences of Contemporary
 Chemistry
 Biblioteca Chimiei
 Materiale Plastice